Core Insights - IMCD N.V. has signed an agreement to acquire 100% of the shares in Tillmanns S.p.A., enhancing its market presence in Italy and unlocking growth potential across industrial and food markets [1][4]. Company Overview - Tillmanns, founded in 1940 and headquartered in Milan, Italy, is a well-established distributor of specialty chemicals, serving key markets such as coatings, construction, food & nutrition, and water treatment [2]. - In 2024, Tillmanns reported annual revenues of approximately EUR 143 million and employs a skilled team of 78 people [3]. Strategic Fit - The acquisition of Tillmanns is a strategic fit for IMCD, as it increases scale and market presence in Italy, complementing IMCD's ambition to deliver value-driven solutions and technical support [4]. - Marcus Jordan, CEO of IMCD, emphasized that Tillmanns brings local expertise, a loyal customer base, and a strong growth platform in industrial, water, and food applications [5]. Financial Performance - IMCD reported revenues of EUR 4,728 million in 2024 and has over 5,100 employees [7].

Press release_IMCD first half year 2025 results • Gross profit up by 5% to EUR 634 million (+7% on a constant currency basis) • Operating EBITA up by +2% to EUR 275 million (+4% on a constant currency basis) • Free cash flow of EUR 173 million (first half 2024: EUR 221 million) • Cash earnings per share at EUR 2.94 (first half 2024: EUR 3.23) • Expanding our footprint across key markets through six completed acquisitions year to date Rotterdam, The Netherlands (30 July 2025) - IMCD N.V. ("IMCD" or "Company" ...

Core Viewpoint - IMCD N.V. has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited, and Chemistry & Health FZ LLC, enhancing its portfolio in the life-sciences industry, particularly in active pharmaceutical ingredients [1][4]. Company Overview - IMCD is a global leader in the distribution and formulation of specialty chemicals and ingredients, headquartered in Rotterdam, The Netherlands [5]. - In 2024, IMCD reported revenues of EUR 4,728 million and employed over 5,100 staff [6]. Trichem Overview - Trichem, founded in 1998 and based in Mumbai, India, specializes in supplying high-quality active pharmaceutical ingredients and pharmaceutical intermediates, along with regulatory assistance for the pharmaceutical markets in India [2]. - The company operates with 36 employees and generated annual revenue of approximately INR 1.7 billion (around EUR 18 million) for the financial year ending 31 March 2025, with 33% of this revenue derived from commission income [3]. Strategic Importance - The acquisition is positioned to strengthen IMCD's presence in the Indian market, which is a major supplier of generic drugs globally, and to leverage Trichem's market expertise and industry relationships [4].

Core Insights - IMCD N.V. has signed an agreement to acquire 100% of the shares in TECOM Ingredients S.A. [1] - The acquisition aims to enhance IMCD's presence in the Iberian market and expand its portfolio with complementary ingredients [3] Company Overview - IMCD is a global leader in the distribution and formulation of specialty chemicals and ingredients, headquartered in Rotterdam, The Netherlands [4] - In 2024, IMCD reported revenues of EUR 4,728 million and employed over 5,100 staff [5] TECOM Overview - TECOM, founded in 1996 and based in Molins de Rei, Spain, is a recognized distributor of ingredients and additives for the food industry, with annual revenues of approximately EUR 18 million in 2024 [2][3] - The company specializes in various applications, including savory, bakery, dairy, and health and nutrition products [2] Strategic Implications - The acquisition is expected to open new avenues for growth and enhance value for customers by combining the expertise of both companies [3] - The transaction is subject to customary closing conditions and is anticipated to close in the second quarter of 2025 [3]